Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics

The rapid growth of COVID-19 cases is causing an increasing death toll and also paralyzing the world economy. De novo drug discovery takes years to move from idea and/or pre-clinic to market, and it is not a short-term solution for the current SARS-CoV-2 pandemic. Drug repurposing is perhaps the onl...

Descripción completa

Detalles Bibliográficos
Autores principales: Oerlemans, Rick, Ruiz-Moreno, Angel Jonathan, Cong, Yingying, Dinesh Kumar, Nilima, Velasco-Velazquez, Marco A., Neochoritis, Constantinos G., Smith, Jolanda, Reggiori, Fulvio, Groves, Matthew R., Dömling, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2020
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130630/
https://www.ncbi.nlm.nih.gov/pubmed/34041486
http://dx.doi.org/10.1039/d0md00367k

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130630/
https://www.ncbi.nlm.nih.gov/pubmed/34041486
http://dx.doi.org/10.1039/d0md00367k

Ejemplares similares